Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Magnetic fields join the fight against breast cancer in first safety trial

NCT ID NCT06332508

Disease control Sponsor: National University Hospital, Singapore Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested whether adding pulsed electromagnetic fields (PEMFs) to standard chemotherapy is safe for people with breast cancer. Fourteen participants received the combination before surgery. The main goal was to check for side effects, not to cure the disease. This study helps pave the way for future research on this potential new treatment approach.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

14 people

The number who actually took part.

Started

Dec 2022

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 99 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Histologically confirmed breast carcinoma of any subtype (any estrogen receptor, progesterone receptor and HER2 receptor status) 2. ECOG 0-1. 3. Non-metastatic disease for which surgery of curative intent is planned upfront or after completion of neoadjuvant chemotherapy 4. Adequate organ function including the following: 1. Bone marrow: 1. Absolute neutrophil (segmented and bands) count (ANC) \>= 1.5 x 10\^9/L 2. Platelets \>= 100 x 10\^9/L 3. Hemoglobin \>= 8 x 10\^9/L 2. Hepatic: 1. Bilirubin \<= 1.5 x upper limit of normal (ULN), 2. ALT or AST \<= 2.5x ULN, (or \<=5 X with liver metastases) 3. Renal: 1. Creatinine \<= 1.5x ULN 5. Signed informed consent from subject or legal representative. 6. Able to comply with study-related procedures. Exclusion Criteria: 1. Pregnancy. 2. Breast feeding. 3. Presence of fungating breast tumor or open wound in breast planned for PEMF. 4. Active bleeding disorder or bleeding site. 5. Second primary malignancy that is clinically detectable at the time of consideration for study enrollment. 6. Major surgery within 28 days prior to study administration. 7. Non-healing wound. 8. Active infection that in the opinion of the investigator would compromise the subject's ability to tolerate therapy. 9. History of significant neurological or mental disorder, including seizures or dementia. 10. Serious concomitant disorders that would compromise the safety of the subject or compromise the subject's ability to complete the study, at the discretion of the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer

Contacts and locations

Locations

  • National University Hospital

    Singapore, Singapore, 119074, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.